Bioxcels Earnings Beat Cant Stop 99.8% Drop in 30 Days

Bioxcel Therapeutics reported its 2025 Q4 earnings on March 27, 2026, showing a significant decline in performance. The company's revenue dropped by 30.1% to $256,000, and its net loss widened to $12.54 million. Despite beating EPS estimates by $0.06, the broader financial outlook remains challenging. The guidance did not include specific revenue or EPS targets but emphasized key regulatory milestones.

Revenue

Bioxcel Therapeutics reported a 30.1% year-over-year decline in total revenue, reaching $256,000 in the fourth quarter of 2025 compared to $366,000 in the same period in 2024. This significant drop highlights continued pressure on the company’s revenue generation capabilities. The decline reflects broader challenges in monetizing its therapeutic offerings amid ongoing investment in research and development. The revenue loss exacerbates the company’s financial strain, especially given the lack of segment-level diversification to cushion the impact.

Earnings/Net Income

The company's earnings per share (EPS) worsened significantly, with losses deepening to -$0.57 per share in 2025 Q4 from -$0.22 per share in 2024 Q4, marking a 162.2% increase in loss per share. Meanwhile, the net loss widened to $12.54 million, a 15.5% increase from the $10.86 million loss recorded in the same quarter of the previous year. These figures underscore a deteriorating financial performance, with the company recording losses for three consecutive years in the same period, highlighting ongoing operational and financial headwinds. The EPS performance indicates a poor outcome for investors.

Price Action

The stock price of Bioxcel Therapeutics has experienced a sharp decline across multiple timeframes. During the latest trading day, it tumbled by 11.27%, followed by a 16.56% drop in the most recent full trading week and a 24.10% plummet month-to-date. The continued downward trend reflects investor concern over the company’s financial performance and uncertain future prospects.

Post-Earnings Price Action Review

The strategy of purchasing Bioxcel Therapeutics (BTAI) shares following the Q4 earnings release, which reported a revenue decline, and holding for 30 days resulted in a substantial loss. Over this period, the investment returned -99.83%, significantly underperforming the market benchmark, which returned 65.35%. The excess return of -165.18% and a CAGR of -72.29% over three years indicate a dramatic depreciation in value. Additionally, the strategy faced an extreme maximum drawdown of 99.86% and a Sharpe ratio of -0.65, both of which underscore the high volatility and risk associated with this investment approach.

CEO Commentary

Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics, highlighted progress made in 2025, particularly in the potential expansion of IGALMI for at-home use and the advancement of Alzheimer’s dementia programs. The company expressed confidence in the at-home market opportunity, citing a third-party assessment of up to 86 million annual addressable episodes. Mehta reiterated the focus on commercial readiness, including hiring an interim Chief Commercial Officer, and emphasized the Alzheimer’s program as a “large market opportunity.” The commentary remained optimistic about IGALMI’s outpatient potential and pipeline differentiation, while acknowledging ongoing R&D investments and cost reductions post-2024.

Guidance

The company outlined forward-looking expectations, including the potential FDA approval of IGALMI’s at-home sNDA by year-end 2026, supported by the SERENITY At-Home Phase 3 trial. It referenced a third-party market assessment projecting 86 million annual episodes of agitation treatable with IGALMI in outpatient settings. Guidance also included advancing the TRANQUILITY Phase 3 trial for Alzheimer’s agitation and preparing for commercial launch readiness. No explicit revenue or EPS guidance was provided, with the focus on regulatory milestones and market expansion timelines.

Additional News

Within the three weeks following the Q4 earnings report, BioXcel Therapeutics did not announce any material M&A activity or executive changes. The company, however, provided updated financial figures in its quarterly press release, including a GAAP EPS of -$0.58, which beat estimates by $0.06, and revenue of $260,000, exceeding expectations by $110,000. The company reported $28.8 million in cash and cash equivalents as of December 31, 2025. Additionally, analysts from several firms maintained or initiated buy ratings on the stock, with price targets ranging from $10 to $66, reflecting continued optimism around the company’s pipeline and potential for future growth.